Combination of trastuzumab, pertuzumab and docetaxel was studied in as phase II IFCT-1703 R2D2 trial which enrolled patients with advanced NSCLC harboring HER2 mutation after progression of disease on ≥ 1 platinum based chemotherapy. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.